Daclizumab induced sarcoidosis

Photo-Induced Sarcoidosis

Corresponding author: Jen-Hung Yang, No. 110, Sec. 1, Jianguo N. Road, Taichung, Taiwan 402, R.O.C. TEL: 886-4-2473-9595 FAX: 886-4-2324-8116 E-mail: mryang@csmu.edu.tw Funding source: none Confl ict of interest: none declared Received: October 09, 2008 Revised: December 22, 2008 Accepted: February 11, 2009 CASE REPORT A 61-year-old woman, who was a farmer, suffered from fl esh to reddish annul...

A Case of Capecitabine-Induced Sarcoidosis

Sarcoidosis is an inflammatory disease involving multiple-organs with an unknown cause. The new onset of sarcoidosis associated with therapeutic agents has been observed in 3 clinical settings; tumor necrosis factor antagonists in autoimmune rheumatologic diseases, interferon alpha with or without ribavirin in patients with chronic hepatitis C or melanoma, and antineoplastic agent-associated sa...

Sarcoidosis induced by tocilizumab: a paradoxical event?

Spotlight on anti-CD25: daclizumab in MS.

Monoclonal antibodies are a promising new class of therapeutic agents that can be employed to target specific molecules of the immune system or any tissue. They are currently being tested in a number of clinical trials in autoimmune diseases such as multiple sclerosis (MS). One of these, the humanized monoclonal anti-CD25 antibody daclizumab (Zenapax), is directed against the interleukin-2 (IL-...

Daclizumab (anti-CD25) in multiple sclerosis.

Multiple sclerosis (MS) is a typical CD4 T cell-mediated autoimmune disease of the central nervous system (CNS) that leads to inflammation, demyelination, axonal damage, glial scarring and a broad range of neurological deficits. While disease-modifying drugs with a good safety profile and moderate efficacy have been available for 20 years now, a growing number of substances with superior therap...